Aellig Natalie C, Balmer Christian, Dodge-Khatami Ali, Rahn Mariette, Prêtre René, Bauersfeld Urs
Division of Pediatric Cardiology, University Children's Hospital, Zurich, Switzerland.
Ann Thorac Surg. 2007 Apr;83(4):1420-3. doi: 10.1016/j.athoracsur.2006.11.042.
Pacemaker (PM) system implantation in neonates and infants is often complicated by hemodynamic instability, small vessel size, and abnormal cardiovascular anatomy. Thus, an open surgical approach for epicardial lead insertion is often required. We assessed the long-term outcomes after epicardial PM implantation in this age group.
Between 1992 and 2004, 22 consecutive patients underwent PM implantation within the first year of life. Bipolar steroid-eluting epicardial leads (Medtronic CapSure Epi 10366 and 4968) were inserted through median sternotomy, the sybxyphoid approach, or thoracotomy, and connected to various pulse generators.
Pacemakers were implanted at a median age of 35 days (range, 1 to 300). Intracardiac anatomy was abnormal in 17 patients. Indications for PM therapy were heart block in 18 patients and sinus node dysfunction in 4 patients. During a median follow-up of 4.6 years (range, 4 days to 12.8 years), 7 devices were replaced owing to end of battery life (n = 6) or elective device repositioning (n = 1), at a median of 4.1 years (range, 1 to 7.8). One dislodged ventricular lead and 2 atrial lead sensing failures were observed. Sensing, pacing thresholds, and lead impedances showed good implant and stable follow-up values.
Pacemaker-associated morbidity is low. Pacemaker system complications with epicardial leads are rare. Battery life is relatively shorter compared with children and adults because of the fast heart rate and complete PM dependency in most of these children. Even for neonates and infants, modern pacemaker therapy is feasible, safe, and effective.
新生儿和婴儿植入起搏器(PM)系统常因血流动力学不稳定、血管细小和心血管解剖结构异常而变得复杂。因此,通常需要采用开放手术方法进行心外膜导线植入。我们评估了该年龄组心外膜PM植入后的长期结果。
1992年至2004年期间,22例连续患者在出生后第一年内接受了PM植入。通过正中胸骨切开术、剑突下途径或开胸术插入双极类固醇洗脱心外膜导线(美敦力CapSure Epi 10366和4968),并连接到各种脉冲发生器。
起搏器植入的中位年龄为35天(范围1至300天)。17例患者存在心脏内解剖结构异常。PM治疗的适应证为18例心脏传导阻滞和4例窦房结功能障碍。在中位随访4.6年(范围4天至12.8年)期间,7台设备因电池寿命结束(n = 6)或择期设备重新定位(n = 1)而更换,中位时间为4.1年(范围1至7.8年)。观察到1根心室导线脱位和2例心房导线感知故障。感知、起搏阈值和导线阻抗显示出良好的植入和稳定的随访值。
起搏器相关的发病率较低。心外膜导线的起搏器系统并发症很少见。由于这些儿童大多数心率快且完全依赖PM,与儿童和成人相比,电池寿命相对较短。即使对于新生儿和婴儿,现代起搏器治疗也是可行、安全和有效的。